UB Paderborn / Katalog / Suche / in CDI

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

The lancet oncology, 2013-07, Vol.14 (8), p.741-748

2013

Volltextzugriff (PDF)

Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer

Radiotherapy and oncology, 2013-11, Vol.109 (2), p.281-285

2013

Volltextzugriff (PDF)

Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database

Journal of clinical oncology, 2011-06, Vol.29 (16), p.2178-2184

2011

Volltextzugriff (PDF)

Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial

Journal of clinical oncology, 2009-12, Vol.27 (36), p.6129-6134

2009

Volltextzugriff (PDF)

Survival End Point Reporting in Randomized Cancer Clinical Trials: A Review of Major Journals

Journal of clinical oncology, 2008-08, Vol.26 (22), p.3721-3726

2008

Volltextzugriff (PDF)

Quality of Life Assessment After Concurrent Chemoradiation for Invasive Bladder Cancer: Results of a Multicenter Prospective Study (GETUG 97-015)

International journal of radiation oncology, biology, physics, 2011, Vol.79 (1), p.172-178

2011

Volltextzugriff (PDF)

Salvage Stereotactic Reirradiation With or Without Cetuximab for Locally Recurrent Head-and-Neck Cancer: A Feasibility Study

International journal of radiation oncology, biology, physics, 2012-09, Vol.84 (1), p.203-209

2012

Volltextzugriff (PDF)

Sentinel lymph node identification using superparamagnetic iron oxide particles versus radioisotope: The French Sentimag feasibility trial

Journal of surgical oncology, 2016-04, Vol.113 (5), p.501-507

2016

Volltextzugriff (PDF)

What does a modified-Fibonacci dose-escalation actually correspond to?

BMC medical research methodology, 2012-07, Vol.12 (1), p.103-103, Article 103

2012

Volltextzugriff (PDF)

A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy

Breast cancer research and treatment, 2015-08, Vol.152 (3), p.569-580

2015

Volltextzugriff (PDF)

Sequential Versus Single High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: Long-Term Results of a Prospective Randomized Trial

Journal of clinical oncology, 2012-03, Vol.30 (8), p.800-805

2012

Volltextzugriff (PDF)

Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials

Biometrics, 2010-06, Vol.66 (2), p.532-540

2010

Volltextzugriff (PDF)

Lobulated Enhancement Evaluation in the Follow-Up of Liver Metastases Treated by Stereotactic Body Radiation Therapy

International journal of radiation oncology, biology, physics, 2015-06, Vol.92 (2), p.292-298

2015

Volltextzugriff (PDF)

Prognostic factors affecting local control of hepatic tumors treated by Stereotactic Body Radiation Therapy

Radiation oncology (London, England), 2012-10, Vol.7 (1), p.166-166, Article 166

2012

Volltextzugriff (PDF)

Identification of a New Panel of Serum Autoantibodies Associated with the Presence of In situ Carcinoma of the Breast in Younger Women

Clinical cancer research, 2009-07, Vol.15 (14), p.4733-4741

2009

Volltextzugriff (PDF)

Gene Expression Signature in Advanced Colorectal Cancer Patients Select Drugs and Response for the Use of Leucovorin, Fluorouracil, and Irinotecan

Journal of clinical oncology, 2007-03, Vol.25 (7), p.773-779

2007

Volltextzugriff (PDF)

Radiation-induced CD8 T-lymphocyte Apoptosis as a Predictor of Breast Fibrosis After Radiotherapy: Results of the Prospective Multicenter French Trial

EBioMedicine, 2015-12, Vol.2 (12), p.1965-1973

2015

Volltextzugriff (PDF)

CD4 and CD8 T-Lymphocyte Apoptosis Can Predict Radiation-Induced Late Toxicity: A Prospective Study in 399 Patients

Clinical cancer research, 2005-10, Vol.11 (20), p.7426-7433

2005

Volltextzugriff (PDF)

Single Nucleotide Polymorphisms, Apoptosis, and the Development of Severe Late Adverse Effects After Radiotherapy

Clinical cancer research, 2008-10, Vol.14 (19), p.6284-6288

2008

Volltextzugriff (PDF)

Impact of RNA degradation on gene expression profiles: Assessment of different methods to reliably determine RNA quality

Journal of biotechnology, 2007-01, Vol.127 (4), p.549-559

2007

Volltextzugriff (PDF)

UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan

Clinical cancer research, 2007-06, Vol.13 (11), p.3269-3275

2007

Volltextzugriff (PDF)

Estrogen Receptor β (ERβ) Level but Not Its ERβcx Variant Helps to Predict Tamoxifen Resistance in Breast Cancer

Clinical cancer research, 2004-09, Vol.10 (17), p.5769-5776

2004

Volltextzugriff (PDF)

Novel Technique for Hepatic Fiducial Marker Placement for Stereotactic Body Radiation Therapy

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.119-125

2014

Volltextzugriff (PDF)

Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome

BMC cancer, 2013-09, Vol.13 (1), p.413-413, Article 413

2013

Volltextzugriff (PDF)

Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial

BMC cancer, 2015-03, Vol.15 (1), p.127-127, Article 127

2015

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer

Conventional-Dose Versus High-Dose Chemotherapy As First Salvage Treatment in Male Patients With Metastatic Germ Cell Tumors: Evidence From a Large International Database

Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial

Survival End Point Reporting in Randomized Cancer Clinical Trials: A Review of Major Journals

Quality of Life Assessment After Concurrent Chemoradiation for Invasive Bladder Cancer: Results of a Multicenter Prospective Study (GETUG 97-015)

Salvage Stereotactic Reirradiation With or Without Cetuximab for Locally Recurrent Head-and-Neck Cancer: A Feasibility Study

Sentinel lymph node identification using superparamagnetic iron oxide particles versus radioisotope: The French Sentimag feasibility trial

What does a modified-Fibonacci dose-escalation actually correspond to?

A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy

Sequential Versus Single High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: Long-Term Results of a Prospective Randomized Trial

Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials

Lobulated Enhancement Evaluation in the Follow-Up of Liver Metastases Treated by Stereotactic Body Radiation Therapy

Prognostic factors affecting local control of hepatic tumors treated by Stereotactic Body Radiation Therapy

Identification of a New Panel of Serum Autoantibodies Associated with the Presence of In situ Carcinoma of the Breast in Younger Women

Gene Expression Signature in Advanced Colorectal Cancer Patients Select Drugs and Response for the Use of Leucovorin, Fluorouracil, and Irinotecan

Radiation-induced CD8 T-lymphocyte Apoptosis as a Predictor of Breast Fibrosis After Radiotherapy: Results of the Prospective Multicenter French Trial

CD4 and CD8 T-Lymphocyte Apoptosis Can Predict Radiation-Induced Late Toxicity: A Prospective Study in 399 Patients

Single Nucleotide Polymorphisms, Apoptosis, and the Development of Severe Late Adverse Effects After Radiotherapy

Impact of RNA degradation on gene expression profiles: Assessment of different methods to reliably determine RNA quality

UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan

Estrogen Receptor β (ERβ) Level but Not Its ERβcx Variant Helps to Predict Tamoxifen Resistance in Breast Cancer

Novel Technique for Hepatic Fiducial Marker Placement for Stereotactic Body Radiation Therapy

Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome

Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial

Suchergebnisse filtern